Bayer earnings hit by tough farm market in fresh challenge for CEO
Adds details and CEO quote on overhaul from paragraph 6
By Ludwig Burger
FRANKFURT, Aug 6 (Reuters) -Bayer BAYGn.DE posted a 16.5% drop in quarterly adjusted earnings on Tuesday, becoming the latest agricultural chemicals supplier to be hit by weak demand due to lower grains prices and adding to the CEO's challenges in his second year in the job.
Bayer boss Bill Anderson has launched a push to speed up decision making and slash corporate bureaucracy to turn around the embattled industrial group, and job cuts gathered pace in the second quarter, according to the group's statement.
The group's April-to-June earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, fell to 2.1 billion euros ($2.3 billion), also dragged lower by negative foreign exchange effects, in line with an average analyst estimate posted on the company's website.
Bayer, which had close to 100,000 staff at the end of 2023, said it had cut the equivalent of 3,200 full-time jobs during the first six months of this year, marking an acceleration after cutting 1,500 jobs during the first quarter.
The CEO, who is slashing hierarchy levels to give product developers and sales people more power, has ruled out any staff reduction targets beyond saying cuts would be significant.
The voluntary redundancies, affecting managers primarily, have so far been consistent with a target to cut 2 billion euros in annual costs from 2026, Anderson said.
"This is exactly what we envisioned," he told a media call.
TOUGH FARMING MARKET
The tough farming market has been felt by rivals including Corteva CTVA.N of the United States, which last week cut full-year forecasts, hurt by lower prices.
A decline in agricultural commodity prices has forced many farmers to rein in their spending on crop chemicals.
BASF, another major competitor, has said herbicide and fungicide sale volumes declined during the April-to-June quarter, normally a key earnings-generating season for the industry.
Bayer confirmed its previous full-year earnings guidance, saying agriculture product margins would recover, excluding earnings from the glyphosate weedkiller, which has been subject to costly legal claims alleging that it causes cancer.
The company's shares were little changed at 0908 GMT, with Deutsche Bank analysts saying in a research note that better-than-expected pharmaceutical sales were broadly offset by a disappointing agriculture business.
Anderson said in March he would hold off for up to three years on previous preparations to break apart the German maker of pharmaceuticals, crop protection products and consumer health remedies.
His focus is instead on changing Bayer's management structure as well as on cutting debt and dealing with a massive wave of U.S. product liability lawsuits even though the U.S. environmental regulator has declared glyphosate safe to use.
Anderson, who became CEO in June 2023, has had a tumultuous start in the job marked by falling share prices and efforts to end the glyphosate litigation. The group also suffered a major setback in drug development late last year.
The CEO, however, clearly won a confidence vote at his first annual general meeting for Bayer in April. Earlier in the year, top-five shareholder Harris Associates came out in strong support for the CEO's course.
Reporting by Ludwig Burger;
Editing by Rachel More and Helen Popper
Ativos relacionados
Últimas notícias
Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.
Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.
Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.
